| Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma New England Journal of Medicine 374 (17), 1621-1634, 2016 | 1215 | 2016 |
| Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label … C Zhou, SS Ramalingam, TM Kim, SW Kim, JCH Yang, GJ Riely, ... JAMA oncology, 2021 | 231 | 2021 |
| Activity and safety of mobocertinib (TAK-788) in previously treated non–small cell lung cancer with EGFR Exon 20 insertion mutations from a Phase I/II trial GJ Riely, JW Neal, DR Camidge, AI Spira, Z Piotrowska, DB Costa, ... Cancer Discovery 11 (7), 1688-1699, 2021 | 182 | 2021 |
| Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients H Avet-Loiseau, NJ Bahlis, WJ Chng, T Masszi, L Viterbo, L Pour, P Ganly, ... Blood 130 (24), 2610-2618, 2017 | 129 | 2017 |
| Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review S Kolluri, J Lin, R Liu, Y Zhang, W Zhang The AAPS Journal 24 (1), 1-10, 2022 | 115 | 2022 |
| Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for … P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ... Blood 126 (23), 727, 2015 | 98 | 2015 |
| Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma S Kumar, P Moreau, P Hari, MV Mateos, H Ludwig, C Shustik, T Masszi, ... British Journal of Haematology 178, 571-582, 2017 | 70 | 2017 |
| Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials J Lin, V Bunn Contemporary Clinical Trials 54, 48-59, 2017 | 67 | 2017 |
| A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated … SK Kumar, JG Berdeja, R Niesvizky, S Lonial, M Hamadani, AK Stewart, ... Blood 120 (21), 332, 2012 | 58 | 2012 |
| Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory … MV Mateos, T Masszi, N Grzasko, M Hansson, I Sandhu, L Pour, L Viterbo, ... Haematologica 102 (10), 1767-1775, 2017 | 57 | 2017 |
| Principal stratum strategy: Potential role in drug development B Bornkamp, K Rufibach, J Lin, Y Liu, DV Mehrotra, S Roychoudhury, ... Pharmaceutical Statistics 20 (4), 737-751, 2021 | 47 | 2021 |
| Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies DC Smith, T Kalebic, JR Infante, LL Siu, D Sullivan, G Vlahovic, JS Kauh, ... Investigational New Drugs 33 (3), 652-663, 2015 | 47 | 2015 |
| Propensity‐score‐based meta‐analytic predictive prior for incorporating real‐world and historical data M Liu, V Bunn, B Hupf, J Lin, J Lin Statistics in Medicine, 2021 | 31 | 2021 |
| Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations. SHI Ou, HM Lin, JL Hong, Y Yin, S Jin, J Lin, M Mehta, D Nguyen, ... Journal of Clinical Oncology 39 (15_suppl), 9098-9098, 2021 | 29 | 2021 |
| Preliminary results from a phase 1b study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/refractory multiple myeloma (RRMM) AY Krishnan, KK Patel, P Hari, S Jagannath, R Niesvizky, RW Silbermann, ... Blood 134, 140, 2019 | 29 | 2019 |
| Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and … SS Ramalingam, C Zhou, TM Kim, SW Kim, JCH Yang, GJ Riely, ... Journal of Clinical Oncology 39 (15_suppl), 9014-9014, 2021 | 28 | 2021 |
| Innovative trial designs and analyses for vaccine clinical development M Liu, Q Li, J Lin, Y Lin, E Hoffman Contemporary Clinical Trials, 2020 | 28 | 2020 |
| Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations C Zhou, S Ramalingam, B Li, J Fang, TM Kim, S Kim, JC Yang, G Riely, ... Journal of Thoracic Oncology 16 (3), S108, 2021 | 27 | 2021 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Anti‐CD38 Cytolytic Antibody TAK‐079 in Healthy Subjects ER Fedyk, L Zhao, A Koch, G Smithson, J Estevam, G Chen, G Lahu, ... British Journal of Clinical Pharmacology 86 (7), 1314-1325, 2020 | 27 | 2020 |
| A General Overview of Adaptive Randomization Design for Clinical Trials J Lin, LA Lin, S Sankoh Journal of Biometrics and Biostatistics 7 (2), 294, 2016 | 26 | 2016 |
